
Akebia Therapeutics has pulled back the veil on data from the second of two Phase 3 clinical trials for its …
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals

